Difference between revisions of "Part:BBa K1781002"

Revision as of 03:44, 21 October 2021

ZHER2 - affibody with affinity to cytoplasmic domain of HER2

ZHER2 was one of the first affibodies created and it binds to the Human Epidermal Growth Factor 2 (HER2). They originate from mutations in the Immunoglobin G Binding Domain of Protein A from Staphylococcus aureus. Affibodies are engineered to bind to larger proteins or peptides where they imitate monoclonal antibodies. They are used in a multitude of therapies in biotechnology to bioimaging. ZHER2 can particular be used as a protein-protein interaction tool, as well as a way to verify antibody interactions as it binds to the cytoplasmic domain of HER2 at a different epitope than the antibodies.

Improvement and New Application for ZHER2

Group: iGEM2021_Greatbay_SCIE
Author: iGEM2021_Greatbay_SCIE
link: Greatbay_SCIE Specific delivery of ZHER2 affibody-conjugated gold nanoparticles to HER2-positive malignant cells imades add The picture above is a review of a project of an Iranian team, which gives us a new enhancement of X-ray radiotherapy by specific delivery of ZHER2 affibody-conjugated gold nanoparticles to HER2-positive malignant cells.Their results confirm the importance of GNP targeting for efficient X-ray radiation therapy of tumor cells. According to the experiment of this team, GNP-ZHER2 can be conjugated with x-ray radiation, which significantly reduces the viability of Her2 - overexpressed cancerous cells, making treatments more effective.

Better drug delivery—Hyperthermia-triggered intracellular delivery of an anticancer agent to HER2+ cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2+ affisomes) images add This new design was raised by a team from the USA.Also, results showed that HER2+ affisome/SK-BR-3 cell complexes have cytosolic delivery at 45 °C, with no effect on cell viability under these conditions. Similarly, DOX-loaded HER2+affisomes showed at least 2- to 3-fold higher accumulation of DOX in SK-BR-3 cells as compared to control liposomes.Therefore, the results prove the better performance of ZHER2 in the drug delivery area, and ZHER2 encompasses both targeting and triggering potential and hence may prove to be viable nano-drug delivery carriers for breast cancer treatment.

Sequence and Features